A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Viremic Adult Subjects With Chronic Hepatitis B Who Are Not Currently on Treatment
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Selgantolimod (Primary) ; Tenofovir alafenamide
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors Gilead Sciences
- 03 Oct 2019 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.
- 30 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2019.